Key Ongoing Clinical Trials in HR-Positive/HER2-Negative Early-Stage Breast Cancer

This slideset accompanies an expert analysis of ongoing clinical trials that are most likely to inform care of patients with HR-positive/HER2-negative early-stage breast cancer.
Denise A. Yardley, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.77 MB
Released: September 22, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AstraZeneca
Lilly
Merck Sharp & Dohme Corp.

Related Content

Enter details about your patient with HER2+ MBC into this online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Komal Jhaveri, MD Heather McArthur, MD, MPH Sara Tolaney, MD, MPH Released: November 23, 2022

Expert commentary with Dr Charles Geyer on the essential need for BRCA testing in early breast cancer to guide adjuvant olaparib decisions, from Clinical Care Options (CCO) and ProCE

Charles E. Geyer, Jr., MD Released: November 17, 2022

A patient describes her journey with early breast cancer and the critical role of good communication between patients and their healthcare providers in this short video by Clinical Care Options (CCO)

person default Zoe Lanham Released: November 16, 2022

Downloadable slides on multidisciplinary approaches to managing high-risk, HR-positive/HER2-negative early breast cancer, from Clinical Care Options, (CCO)

Erika P. Hamilton, MD
Program Director
Joyce O'Shaughnessy, MD
Program Director
Released: November 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings